SOLENO THERAPEUTICS INC (SLNO) Stock Overview
USA - NASDAQ:SLNO - US8342033094 - Common Stock
SLNO Key Statistics, Chart & Performance
The current stock price of SLNO is 64.23 USD. In the past month the price increased by 1.5%. In the past year, price increased by 15.91%.
SLNO Latest News, Press Relases and Analysis
SLNO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.54 | 402.89B | ||
| AMGN | AMGEN INC | 13.42 | 157.52B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.08 | 108.93B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.69 | 61.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
| ARGX | ARGENX SE - ADR | 88.9 | 50.41B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.16B | ||
| INSM | INSMED INC | N/A | 33.69B | ||
| NTRA | NATERA INC | N/A | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.32B | ||
| BIIB | BIOGEN INC | 9.41 | 22.08B |
Related stock screener links
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 92
Phone: 16502138444
SOLENO THERAPEUTICS INC / SLNO FAQ
What does SOLENO THERAPEUTICS INC do?
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
What is the current price of SLNO stock?
The current stock price of SLNO is 64.23 USD. The price increased by 0.9% in the last trading session.
Does SOLENO THERAPEUTICS INC pay dividends?
SLNO does not pay a dividend.
How is the ChartMill rating for SOLENO THERAPEUTICS INC?
SLNO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of SOLENO THERAPEUTICS INC (SLNO) based on its PE ratio?
SOLENO THERAPEUTICS INC (SLNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.14).
What is the ownership structure of SOLENO THERAPEUTICS INC (SLNO)?
You can find the ownership structure of SOLENO THERAPEUTICS INC (SLNO) on the Ownership tab.
SLNO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO is a bad performer in the overall market: 75.43% of all stocks are doing better.
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLNO. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of -4.14. The EPS decreased by -69.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.49% | ||
| ROE | -75.41% | ||
| Debt/Equity | 0.21 |
SLNO Forecast & Estimates
17 analysts have analysed SLNO and the average price target is 121.1 USD. This implies a price increase of 88.54% is expected in the next year compared to the current price of 64.23.